These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 350729)

  • 1. Antithrombin III: critical review of assay methods. Significance of variations in health and disease.
    Odegård OR; Abildgaard U
    Haemostasis; 1978; 7(2-3):127-34. PubMed ID: 350729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated antithrombin III assay with a centrifugal analyser.
    Odegård OR; Rosenlund B; Ervik E
    Haemostasis; 1978; 7(4):202-9. PubMed ID: 658785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases.
    Saxena V; Mishra DK; Subramanya H; Satyanarayana S; Sharma A
    Indian J Pathol Microbiol; 2004 Apr; 47(2):210-2. PubMed ID: 16295470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticoagulant effect of heparin + antithrombin III using purified fibrinogen as substrate.
    Andersen P; Godal HC
    Haemostasis; 1977; 6(6):329-38. PubMed ID: 611046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antithrombin III content of cryoprecipitate prepared from blood collected with and without heparin.
    Cosgriff TM; Hodgson LA; West JV
    Vox Sang; 1983; 44(2):98-101. PubMed ID: 6402859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
    Tran TH; Duckert F
    Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifactor Xa activity measured with amidolytic methods.
    Odegård OR; Lie M; Abildgaard U
    Haemostasis; 1976; 5(5):265-75. PubMed ID: 1017722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin cofactor activity measured with an amidolytic method.
    Odegard OR; Lie M; Abildgaard U
    Thromb Res; 1975 Apr; 6(4):287-94. PubMed ID: 49087
    [No Abstract]   [Full Text] [Related]  

  • 9. On the clinical significance of acquired antithrombin deficiency.
    Sørum Y; Handeland GF; Abildgaard U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):797-805. PubMed ID: 6083956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-enhanced inhibitors during reversible disseminated intravascular coagulation.
    Marbet GA; Griffith MJ; Roberts HR
    Scand J Clin Lab Invest Suppl; 1985; 178():95-8. PubMed ID: 3867125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal heparin cofactor activity in disseminated intravascular coagulation and cirrhosis.
    Braunstein KM; Eurenius K
    Am J Clin Pathol; 1976 Sep; 66(3):488-94. PubMed ID: 60879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation.
    Bick RL; Kovacs I; Fekete LF
    Thromb Res; 1976 Jun; 8(6):745-56. PubMed ID: 60793
    [No Abstract]   [Full Text] [Related]  

  • 14. Antithrombin.
    Hepner M; Karlaftis V
    Methods Mol Biol; 2013; 992():355-64. PubMed ID: 23546728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple amidolytic method for the determination of functional active antithrombin III.
    Abildaard U; Lie M; Odegård OR
    Scand J Clin Lab Invest; 1976 Jan; 36(1):109-12. PubMed ID: 815998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic peptide substrates in hemostatic testing.
    Fareed J; Messmore HL; Walenga JM; Bermes EW
    Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a new laboratory test to evaluate antithrombin resistance in plasma.
    Murata M; Takagi A; Suzuki A; Okuyama E; Takagi Y; Ando Y; Kato I; Nakamura Y; Murate T; Matsushita T; Saito H; Kojima T
    Thromb Res; 2014 Feb; 133(2):293-8. PubMed ID: 24325876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory determination of heparin cofactor II.
    Ezenagu LC; Brandt JT
    Arch Pathol Lab Med; 1986 Dec; 110(12):1149-51. PubMed ID: 3778142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antithrombin III assays using biological and chromogenic substrates.
    Philo RD; Gaffney PJ
    Br J Haematol; 1982 Jan; 50(1):147-56. PubMed ID: 7055531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.